A phase I and pharmacologic study of 9-aminocamptothecin administered as a 120-h infusion weekly to adult cancer patients.
Thomas RR, Dahut W, Harold N, Grem JL, Monahan BP, Liang M, Band RA, Cottrell J, Llorens V, Smith JA, Corse W, Arbuck SG, Wright J, Chen AP, Shapiro JD, Hamilton JM, Allegra CJ, Takimoto CH.
Thomas RR, et al. Among authors: hamilton jm.
Cancer Chemother Pharmacol. 2001 Sep;48(3):215-22. doi: 10.1007/s002800100329.
Cancer Chemother Pharmacol. 2001.
PMID: 11592343
Clinical Trial.